Published in Gastroenterology on April 06, 2013
Hepatocellular carcinoma: clinical frontiers and perspectives. Gut (2014) 5.79
High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions. Nat Commun (2013) 3.06
Integration of tumour and viral genomic characterizations in HBV-related hepatocellular carcinomas. Gut (2014) 2.19
A genomic and clinical prognostic index for hepatitis C-related early-stage cirrhosis that predicts clinical deterioration. Gut (2014) 1.84
Hepatocellular carcinoma review: current treatment, and evidence-based medicine. World J Gastroenterol (2014) 1.66
Unique genomic profile of fibrolamellar hepatocellular carcinoma. Gastroenterology (2014) 1.59
Advances in targeted therapies for hepatocellular carcinoma in the genomic era. Nat Rev Clin Oncol (2015) 1.33
Targeting the mTOR pathway in hepatocellular carcinoma: current state and future trends. J Hepatol (2013) 1.22
Update on biomarkers of hepatocellular carcinoma. Clin Gastroenterol Hepatol (2013) 1.18
Prognostic factors for hepatocellular carcinoma recurrence. World J Gastroenterol (2014) 1.06
Liver cancer: Approaching a personalized care. J Hepatol (2015) 1.05
Transcriptome profiling of archived sectioned formalin-fixed paraffin-embedded (AS-FFPE) tissue for disease classification. PLoS One (2014) 1.01
Recent advances in multidisciplinary management of hepatocellular carcinoma. World J Hepatol (2015) 0.98
Hepatocellular carcinoma: Advances in diagnosis, management, and long term outcome. World J Hepatol (2015) 0.96
Current biomarkers for hepatocellular carcinoma: Surveillance, diagnosis and prediction of prognosis. World J Hepatol (2015) 0.90
The changing landscape of hepatocellular carcinoma: etiology, genetics, and therapy. Am J Pathol (2013) 0.89
Novel aspects of the liver microenvironment in hepatocellular carcinoma pathogenesis and development. Int J Mol Sci (2014) 0.89
A computed tomography radiogenomic biomarker predicts microvascular invasion and clinical outcomes in hepatocellular carcinoma. Hepatology (2015) 0.87
Molecular classification of hepatocellular carcinoma: potential therapeutic implications. Hepat Oncol (2015) 0.84
Prognosis of Early-Stage Hepatocellular Carcinoma: The Clinical Implications of Substages of Barcelona Clinic Liver Cancer System Based on a Cohort of 1265 Patients. Medicine (Baltimore) (2015) 0.83
Staging systems for hepatocellular carcinoma: Current status and future perspectives. World J Hepatol (2015) 0.82
SALL4 Expression in Hepatocellular Carcinomas Is Associated with EpCAM-Positivity and a Poor Prognosis. J Pathol Transl Med (2015) 0.82
A comparison of clinical manifestations and prognoses between patients with hepatocellular carcinoma and Child-Pugh scores of 5 or 6. Medicine (Baltimore) (2014) 0.81
Modeling a human hepatocellular carcinoma subset in mice through coexpression of met and point-mutant β-catenin. Hepatology (2016) 0.81
Viral expression and molecular profiling in liver tissue versus microdissected hepatocytes in hepatitis B virus-associated hepatocellular carcinoma. J Transl Med (2014) 0.80
ALDH3A1 is overexpressed in a subset of hepatocellular carcinoma characterised by activation of the Wnt/ß-catenin pathway. Virchows Arch (2013) 0.79
Monocarboxylate transporter 4 predicts poor prognosis in hepatocellular carcinoma and is associated with cell proliferation and migration. J Cancer Res Clin Oncol (2014) 0.78
Body Composition Features Predict Overall Survival in Patients With Hepatocellular Carcinoma. Clin Transl Gastroenterol (2016) 0.77
Identifying prognostic features by bottom-up approach and correlating to drug repositioning. PLoS One (2015) 0.77
Next generation sequencing, inter-tumor heterogeneity and prognosis of hepatitis B related hepatocellular carcinoma. Chin J Cancer Res (2014) 0.77
Overexpression of phosphatidylinositol 4-kinase type IIIα is associated with undifferentiated status and poor prognosis of human hepatocellular carcinoma. BMC Cancer (2014) 0.76
Clinical implications of basic research in hepatocellular carcinoma. J Hepatol (2015) 0.76
Systems biology for hepatologists. Hepatology (2014) 0.76
An individualized prognostic signature and multi‑omics distinction for early stage hepatocellular carcinoma patients with surgical resection. Oncotarget (2016) 0.76
Common Molecular Subtypes Among Asian Hepatocellular Carcinoma and Cholangiocarcinoma. Cancer Cell (2017) 0.75
Molecular Profiling and Research of Therapeutic Targets. Dig Dis (2015) 0.75
Comprehensive characterization of hepatitis B virus-associated multifocal hepatocellular carcinoma using a multi-omics strategy. Ann Transl Med (2015) 0.75
Overexpression of Leucine-Rich Repeat-Containing G Protein-Coupled Receptor 5 (LGR5) Represents a Typical Wnt/β-Catenin Pathway-Activated Hepatocellular Carcinoma. Liver Cancer (2014) 0.75
Immunohistochemistry panel segregates molecular types of hepatocellular carcinoma in Brazilian autopsy cases. World J Gastroenterol (2016) 0.75
A Global Risk Score (GRS) to Simultaneously Predict Early and Late Tumor Recurrence Risk after Resection of Hepatocellular Carcinoma. Transl Oncol (2016) 0.75
Systemic treatment for hepatocellular carcinoma: Still unmet expectations. World J Hepatol (2017) 0.75
Hepatocellular carcinoma: can circulating tumor cells and radiogenomics deliver personalized care? Am J Clin Oncol (2015) 0.75
The impact of esophagogastric varices on the prognosis of patients with hepatocellular carcinoma. Sci Rep (2017) 0.75
Anti-GPC3-CAR T Cells Suppress the Growth of Tumor Cells in Patient-Derived Xenografts of Hepatocellular Carcinoma. Front Immunol (2017) 0.75
Personalized management of hepatocellular carcinoma based on molecular information: future prospects. Clin Liver Dis (Hoboken) (2015) 0.75
NGS-based transcriptome profiling reveals biomarkers for companion diagnostics of the TGF-β receptor blocker galunisertib in HCC. Cell Death Dis (2017) 0.75
Molecular diagnostic algorithms in hepatocellular carcinoma: dead-end street or light at the end of the tunnel? Gastroenterology (2013) 0.75
Metalloproteinase meprin α regulates migration and invasion of human hepatocarcinoma cells and is a mediator of the oncoprotein Reptin. Oncotarget (2017) 0.75
The impact of clinically significant portal hypertension on the prognosis of patients with hepatocellular carcinoma after radiofrequency ablation: a propensity score matching analysis. Eur Radiol (2016) 0.75
Validation and ranking of seven staging systems of hepatocellular carcinoma. Oncol Lett (2017) 0.75
Role of S100A3 in human hepatocellular carcinoma and the anticancer effect of sodium cantharidinate. Exp Ther Med (2017) 0.75
Imaging-based surrogate markers of transcriptome subclasses and signatures in hepatocellular carcinoma: preliminary results. Eur Radiol (2017) 0.75
A Surgical Perspective on Targeted Therapy of Hepatocellular Carcinoma. Diseases (2015) 0.75
Liver Cancer: Molecular Characterization, Clonal Evolution and Cancer Stem Cells. Cancers (Basel) (2017) 0.75
Sorafenib in advanced hepatocellular carcinoma. N Engl J Med (2008) 54.30
Signatures of mutational processes in human cancer. Nature (2013) 21.63
International network of cancer genome projects. Nature (2010) 20.35
Hepatocellular carcinoma. Lancet (2012) 18.09
KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res (2006) 13.98
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol (2010) 13.25
Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med (2003) 12.17
KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol (2008) 10.29
Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis (2010) 9.73
Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med (2008) 9.20
Large-scale genotyping identifies 41 new loci associated with breast cancer risk. Nat Genet (2013) 8.24
Integrative annotation of 21,037 human genes validated by full-length cDNA clones. PLoS Biol (2004) 7.17
Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology (2002) 6.92
Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: Prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma. Hepatology (2008) 6.75
Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma. Nat Genet (2012) 6.65
Lin28 promotes transformation and is associated with advanced human malignancies. Nat Genet (2009) 6.35
Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol (2008) 5.93
Amoxicillin plus clavulanic acid versus appendicectomy for treatment of acute uncomplicated appendicitis: an open-label, non-inferiority, randomised controlled trial. Lancet (2011) 5.89
Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther (2008) 5.78
Genotype-phenotype correlation in hepatocellular adenoma: new classification and relationship with HCC. Hepatology (2006) 5.46
Frequent in-frame somatic deletions activate gp130 in inflammatory hepatocellular tumours. Nature (2008) 5.38
The international position on laparoscopic liver surgery: The Louisville Statement, 2008. Ann Surg (2009) 5.33
MicroRNA profiling in hepatocellular tumors is associated with clinical features and oncogene/tumor suppressor gene mutations. Hepatology (2008) 5.28
Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J Hepatol (2006) 5.17
Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg (2004) 5.10
Resection of hepatocellular cancer ≤2 cm: results from two Western centers. Hepatology (2013) 5.05
Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology (2002) 4.83
Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. Hepatology (2007) 4.73
Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology (2009) 4.50
Liver cirrhosis: intravoxel incoherent motion MR imaging--pilot study. Radiology (2008) 4.46
Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial. J Clin Oncol (2006) 4.42
Focal gains of VEGFA and molecular classification of hepatocellular carcinoma. Cancer Res (2008) 4.35
Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nat Genet (2013) 4.35
Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology (2008) 4.03
Genome-wide molecular profiles of HCV-induced dysplasia and hepatocellular carcinoma. Hepatology (2007) 3.85
Genome-wide association studies identify four ER negative-specific breast cancer risk loci. Nat Genet (2013) 3.81
Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. Cancer Res (2009) 3.77
Genomics and signaling pathways in hepatocellular carcinoma. Semin Liver Dis (2007) 3.75
Tumor progression while on chemotherapy: a contraindication to liver resection for multiple colorectal metastases? Ann Surg (2004) 3.72
Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study. J Clin Oncol (2013) 3.71
CCR1 and CCR5 promote hepatic fibrosis in mice. J Clin Invest (2009) 3.62
Focus on hepatocellular carcinoma. Cancer Cell (2004) 3.49
Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study. J Clin Oncol (2013) 3.45
A conditional transposon-based insertional mutagenesis screen for genes associated with mouse hepatocellular carcinoma. Nat Biotechnol (2009) 3.44
Genomic portrait of resectable hepatocellular carcinomas: implications of RB1 and FGF19 aberrations for patient stratification. Hepatology (2014) 3.31
SDH mutations establish a hypermethylator phenotype in paraganglioma. Cancer Cell (2013) 3.24
Hepatocellular adenoma subtype classification using molecular markers and immunohistochemistry. Hepatology (2007) 3.18
High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions. Nat Commun (2013) 3.06
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial. J Hepatol (2012) 3.04
Nomenclature of the finer branches of the biliary tree: canals, ductules, and ductular reactions in human livers. Hepatology (2004) 3.00
Gene expression classification of colon cancer into molecular subtypes: characterization, validation, and prognostic value. PLoS Med (2013) 2.96
Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab. J Clin Oncol (2009) 2.92
Chemoembolization for hepatocellular carcinoma. Gastroenterology (2004) 2.89
Bi-allelic inactivation of TCF1 in hepatic adenomas. Nat Genet (2002) 2.85